Ramucirumab: a Novel Anti-Angiogenic Agent in the Treatment of Metastatic Colorectal Cancer

Gaurav Goel, Aman Chauhan, Peter Hosein

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Angiogenesis is a multistep process that plays a key role in cancer growth and metastases. It is mediated through multiple vascular endothelial growth factor receptors (VEGFRs) and their ligands. The expression of VEGFR-2 is upregulated in tumor endothelial cells, and it is considered to be the primary receptor driving malignant angiogenesis. Ramucirumab (IMC-1121B, LY3009806) is a fully human monoclonal antibody that directly binds to VEGFR-2 with high affinity and specificity. It is also the most recent addition to our armamentarium of anti-angiogenic drugs approved for the treatment of metastatic colorectal cancer (CRC). The aim of this review is to summarize the pre-clinical and clinical development of ramucirumab and discuss its place in the current treatment paradigm for metastatic CRC.

Original languageEnglish (US)
Pages (from-to)232-240
Number of pages9
JournalCurrent Colorectal Cancer Reports
Volume12
Issue number5
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Keywords

  • Angiogenesis
  • Colorectal cancer
  • IMC-1121B
  • Monoclonal antibody
  • RAISE
  • Ramucirumab
  • Vascular endothelial growth factor receptor
  • VEGF
  • VEGFR-2

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Ramucirumab: a Novel Anti-Angiogenic Agent in the Treatment of Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

  • Cite this